Company intelligence / Profile preview

Pramand

Bedford, Massachusetts, United Statespramandllc.com ↗

Ownership: Private
Development stage: Commercial

Overview

Pramand has developed and launched the CraniSeal™ Dural Sealant System, an absorbable polyethylene glycol hydrogel for use as an adjunct to sutured dural repair in cranial surgery. The product received Pre-Market Approval (PMA) as a Class 3 medical device in just 3.5 years—significantly faster than average—and leverages proven hydrogel technology with a long record of safety and efficacy[3].

Therapeutic areas: Neurology
Modalities: DeviceHydrogel-based medical device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

CraniSeal

Commercial

Indications: Cranial surgery dural repair

Beyond the preview

Go deeper on Pramand.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pramand.

Explore the full profile